Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357759 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
A Phase 1 study of Rheumatoid Arthritis, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT01357759: Completed Phase 1 study of Rheumatoid Arthritis, sponsored by Morphotek.
NCT01357759 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Morphotek. The registered enrollment target is 20 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01357759, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy male and or female subjects and subjects with Rheumatoid Arthritis (RA) to determine the safety and tolerability of MORAb-022.
Conditions Studied
Interventions
- DRUG MORAb-022
Study Locations (5)
California
- Axis Clinical Trials - Los Angeles
Florida
- Seaview Jacksonville, LLC - Jacksonville
Oklahoma
- Lynn Health Science Institute - Oklahoma City
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Other
- Pharmaceutical Research Associates Group B.V. - Zuidlaren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT01357759 record still lists
NCT01357759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which MORAb-022 is the first listed.
NCT01357759 lists 5 locations in 5 states (California, Florida, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT01357759 about?
NCT01357759 is a clinical study titled "Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects". This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy male and or female subjects and subjects with Rheumatoid Arthritis (RA) to determine the safety and tolerability of MORAb-022.
What is the current status of trial NCT01357759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-05. Estimated completion is 2014-07.
What conditions does trial NCT01357759 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01357759?
The interventions under investigation include: MORAb-022 (DRUG).
Who is sponsoring clinical trial NCT01357759?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01357759 being conducted?
This trial has 5 study locations across California, Florida, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01357759's enrollment target sits among peer trials
20 177th of 197 higher than 18 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia